About Phibro Animal Health Corporation
https://www.pahc.comPhibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
CEO
Jack Clifford Bendheim
Compensation Summary
(Year 2025)
ETFs Holding This Stock
Summary
Showing Top 3 of 157
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
JP Morgan
Overweight
Morgan Stanley
Equal Weight
Barclays
Underweight
B of A Securities
Underperform
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:3.5M
Value:$139.72M
BLACKROCK, INC.
Shares:3.43M
Value:$136.6M
BLACKROCK FUND ADVISORS
Shares:1.71M
Value:$68.23M
Summary
Showing Top 3 of 264
About Phibro Animal Health Corporation
https://www.pahc.comPhibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $363.89M ▼ | $71.45M ▼ | $26.53M ▲ | 7.29% ▲ | $0.65 ▲ | $62.58M ▲ |
| Q4-2025 | $378.7M ▲ | $76.29M ▲ | $17.22M ▼ | 4.55% ▼ | $0.42 ▼ | $44.71M ▼ |
| Q3-2025 | $347.82M ▲ | $71.05M ▼ | $20.88M ▲ | 6% ▲ | $0.52 ▲ | $51.38M ▲ |
| Q2-2025 | $309.26M ▲ | $76.34M ▲ | $3.19M ▼ | 1.03% ▼ | $0.08 ▼ | $25.58M ▼ |
| Q1-2025 | $260.43M | $65.8M | $6.97M | 2.68% | $0.17 | $26.8M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $85.27M ▲ | $1.39B ▲ | $1.07B ▼ | $311.68M ▲ |
| Q4-2025 | $77.04M ▲ | $1.36B ▲ | $1.08B ▲ | $285.68M ▲ |
| Q3-2025 | $70.35M ▲ | $1.32B ▲ | $1.05B ▲ | $265.99M ▲ |
| Q2-2025 | $67.07M ▼ | $1.29B ▲ | $1.04B ▲ | $246.8M ▼ |
| Q1-2025 | $89.84M | $966.29M | $707.76M | $258.53M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $26.53M ▲ | $9.3M ▼ | $-21.01M ▼ | $16.34M ▲ | $4.73M ▼ | $-4.5M ▼ |
| Q4-2025 | $17.22M ▼ | $21.27M ▼ | $-7.03M ▲ | $-7.77M ▲ | $7.68M ▲ | $8.13M ▼ |
| Q3-2025 | $20.88M ▲ | $43.15M ▲ | $-18.25M ▲ | $-32.22M ▼ | $-6.72M ▼ | $35.41M ▲ |
| Q2-2025 | $3.19M ▼ | $3.08M ▼ | $-260.47M ▼ | $276.32M ▲ | $15.24M ▲ | $-4.75M ▼ |
| Q1-2025 | $6.97M | $12.62M | $-2.93M | $-29.2M | $-18.78M | $3.04M |
Revenue by Products
| Product | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 |
|---|---|---|---|---|
 Vaccines | $30.00M ▲ | $30.00M ▲ | $40.00M ▲ | $40.00M ▲ |
Revenue by Geography
| Region | Q3-2025 | Q4-2025 | Q2-2025 | Q1-2026 |
|---|---|---|---|---|
 Asia Pacific | $30.00M ▲ | $40.00M ▲ | $20.00M ▼ | $30.00M ▲ |
 EMEA | $40.00M ▲ | $60.00M ▲ | $30.00M ▼ | $40.00M ▲ |
 Latin America and Canada | $70.00M ▲ | $80.00M ▲ | $70.00M ▼ | $90.00M ▲ |
 UNITED STATES | $210.00M ▲ | $200.00M ▼ | $180.00M ▼ | $200.00M ▲ |
CEO
Jack Clifford Bendheim
Compensation Summary
(Year 2025)
ETFs Holding This Stock
Summary
Showing Top 3 of 157
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
JP Morgan
Overweight
Morgan Stanley
Equal Weight
Barclays
Underweight
B of A Securities
Underperform
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:3.5M
Value:$139.72M
BLACKROCK, INC.
Shares:3.43M
Value:$136.6M
BLACKROCK FUND ADVISORS
Shares:1.71M
Value:$68.23M
Summary
Showing Top 3 of 264